<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Thursday, Feb 6th, 2020 at 11:40
Sheraton San Diego Hotel & Marina, San Diego, CA

Interpreting the complexity of cancer with blood-based biomarkers for both tumor and immune profiling

Key points:

  • An introduction to Biodesix & our approach to blood-based molecular testing
  • Why it’s important to profile both tumor & immune biomarkers
  • Bringing blood-based diagnostics from discovery to the clinic with reimbursement

 

 

Speaker: Linda Traylor, Ph.D. - VP, Clinical Development & Medical Affairs at Biodesix

Dr. Traylor is a published scientist and has served as a Medical and Clinical Affairs professional in healthcare industry for more than 20 years.  Her career has spanned big pharma companies, mid-sized pharma, cell therapy and medical devices, and cancer diagnostics. 

She is passionate in the belief that the success of clinical research moving forward is completely dependent on appropriate use of biomarkers, advanced technology and real-world data collection. 

At Biodesix, as the head of clinical development and medical affairs, Dr. Traylor works cross-functionally to advance diagnostics from early stage development to post-market clinical utility studies, constantly exploring ways to implement new tools to maximize study design for optimal patient outcomes. 

Dr. Traylor joined Biodesix in 2015 to contribute to their multi-omic approach for identifying clinically relevant biological signatures that robustly characterize disease states and response to therapies, which she considers the new norm for clinical research and precision medicine.